Fig. 2From: Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot StudyMean Change in VA from Baseline with 95% C.I. (Observed values). This figure demonstrates the change in CST from baseline for the sirolimus and anti-VEGF groups. There is minimal change in CST for the anti-VEGF group in contrast to the CST decrease in the sirolimus groupBack to article page